Long-term effect of mass azithromycin distributions for childhood mortality on antibiotic resistance

Biannual mass azithromycin distributions reduce childhood mortality in Sub-Saharan Africa. However, stakeholders have struggled to balance this short-term benefit against the potential long-term risk of antibiotic resistance. Here, we monitor resistance in 286 community surveys in Niger over 8 years of biannual azithromycin distributions to pre-school children. Communities were randomized to either azithromycin or placebo at 3 timepoints, allowing assessment of the effects of recent treatment, cumulative treatment, and secular trend. Macrolide resistance genes found in the stool of pre-school children increased during the first 3 years of intervention (the first 6 biannual distributions). Assessment at 4½, 6, and 8 years (after 9, 11, and 15 biannual distributions, respectively) failed to detect any further incremental increase. When distributions were discontinued, macrolide resistance decreased to pre-treatment levels. Beta-lactam resistance increased significantly over the 8 years. This increase was not associated with the mass azithromycin distributions and may represent a secular trend in the region. Mass azithromycin distribution for childhood mortality clearly selects for macrolide-resistant bacteria. This resistance apparently plateaus after 3 years of intervention, remains limited to macrolide antibiotics, and returns to baseline after distributions are discontinued. Monitoring can inform whether the benefit of improved childhood survival with azithromycin distributions continues to outweigh any long-term harm from antibiotic resistance.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-10021703/v1
Primary Topic
Antibiotic Use and Resistance
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Long-term effect of mass azithromycin distributions for childhood mortality on antibiotic resistance

Ahmed Mamane Arzika, Benjamin F. Arnold, Ariktha Srivathsan, Catherine A. Cook et al.
Research Square
Antibiotic Use and Resistance
preprint

Long-term effect of mass azithromycin distributions for childhood mortality on antibiotic resistance

Ahmed Mamane Arzika, Benjamin F. Arnold, Ariktha Srivathsan, Catherine A. Cook, Elodie Lebas, Armin J. Hinterwirth, Thuy A. Doan, Ramatou Maliki, Sani Ousmane, Travis C. Porco, Jeremy David Keenan, Thomas M. Lietman, Paul M. Emerson, Kieran Sunanda O’Brien, Brittany Faye Peterson, Abdou Amza, Milan Hilde-Jones
preprint en

Abstract

Biannual mass azithromycin distributions reduce childhood mortality in Sub-Saharan Africa. However, stakeholders have struggled to balance this short-term benefit against the potential long-term risk of antibiotic resistance. Here, we monitor resistance in 286 community surveys in Niger over 8 years of biannual azithromycin distributions to pre-school children. Communities were randomized to either azithromycin or placebo at 3 timepoints, allowing assessment of the effects of recent treatment, cumulative treatment, and secular trend. Macrolide resistance genes found in the stool of pre-school children increased during the first 3 years of intervention (the first 6 biannual distributions). Assessment at 4½, 6, and 8 years (after 9, 11, and 15 biannual distributions, respectively) failed to detect any further incremental increase. When distributions were discontinued, macrolide resistance decreased to pre-treatment levels. Beta-lactam resistance increased significantly over the 8 years. This increase was not associated with the mass azithromycin distributions and may represent a secular trend in the region. Mass azithromycin distribution for childhood mortality clearly selects for macrolide-resistant bacteria. This resistance apparently plateaus after 3 years of intervention, remains limited to macrolide antibiotics, and returns to baseline after distributions are discontinued. Monitoring can inform whether the benefit of improved childhood survival with azithromycin distributions continues to outweigh any long-term harm from antibiotic resistance.

Research Square
University of California, San Francisco (US), Centre de Recherche Médicale et Sanitaire (NE), International Trachoma Initiative (ET), International Trachoma Initiative (US)
Antibiotic Use and Resistance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon